Combination cediranib and olaparib versus olaparib alone for women with recurrent platinum-sensitive ovarian cancer: a randomised phase 2 studyJoyce F. Liu, Ursula A. Matulonis, B.J. Rimel et al.|The Lancet Oncology|2014Cited by 586
A randomized phase 2 trial comparing efficacy of the combination of the PARP inhibitor olaparib and the antiangiogenic cediranib against olaparib alone in recurrent platinum-sensitive ovarian cancer.Joyce F. Liu, Ursula A. Matulonis, William T. Barry et al.|Journal of Clinical Oncology|2014Cited by 22
A randomized phase 2 trial comparing efficacy of the combination of the PARP inhibitor olaparib and the antiangiogenic cediranib against olaparib alone in recurrent platinum-sensitive ovarian cancer.Joyce F. Liu, Ursula A. Matulonis, William T. Barry et al.|Journal of Clinical Oncology|2014Cited by 13